AU2010236734B2 - 5-HT4 receptor agonist compounds for treatment of cognitive disorders - Google Patents

5-HT4 receptor agonist compounds for treatment of cognitive disorders Download PDF

Info

Publication number
AU2010236734B2
AU2010236734B2 AU2010236734A AU2010236734A AU2010236734B2 AU 2010236734 B2 AU2010236734 B2 AU 2010236734B2 AU 2010236734 A AU2010236734 A AU 2010236734A AU 2010236734 A AU2010236734 A AU 2010236734A AU 2010236734 B2 AU2010236734 B2 AU 2010236734B2
Authority
AU
Australia
Prior art keywords
compound
patient
scopolamine
disease
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010236734A
Other languages
English (en)
Other versions
AU2010236734A1 (en
AU2010236734A8 (en
Inventor
David Beattie
Ray Chang
Robert Murray Mckinnell
Fei Shen
Jacqueline A. M. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Biopharma R&D IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D IP LLC filed Critical Theravance Biopharma R&D IP LLC
Publication of AU2010236734A1 publication Critical patent/AU2010236734A1/en
Publication of AU2010236734A8 publication Critical patent/AU2010236734A8/en
Assigned to THERAVANCE BIOPHARMA R&D IP, LLC reassignment THERAVANCE BIOPHARMA R&D IP, LLC Request for Assignment Assignors: THERAVANCE, INC.
Application granted granted Critical
Publication of AU2010236734B2 publication Critical patent/AU2010236734B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010236734A 2009-04-13 2010-04-12 5-HT4 receptor agonist compounds for treatment of cognitive disorders Ceased AU2010236734B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US61/168,741 2009-04-13
US29255910P 2010-01-06 2010-01-06
US61/292,559 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Publications (3)

Publication Number Publication Date
AU2010236734A1 AU2010236734A1 (en) 2011-11-03
AU2010236734A8 AU2010236734A8 (en) 2012-02-16
AU2010236734B2 true AU2010236734B2 (en) 2015-06-11

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010236734A Ceased AU2010236734B2 (en) 2009-04-13 2010-04-12 5-HT4 receptor agonist compounds for treatment of cognitive disorders

Country Status (24)

Country Link
US (2) US8404711B2 (enExample)
EP (1) EP2419104B1 (enExample)
JP (1) JP2012523437A (enExample)
KR (1) KR20120017421A (enExample)
CN (2) CN102395371A (enExample)
AU (1) AU2010236734B2 (enExample)
BR (1) BRPI1013777A8 (enExample)
CA (1) CA2758321A1 (enExample)
CY (1) CY1119800T1 (enExample)
DK (1) DK2419104T3 (enExample)
ES (1) ES2654930T3 (enExample)
HR (1) HRP20180018T1 (enExample)
HU (1) HUE038141T2 (enExample)
IL (1) IL215660A0 (enExample)
LT (1) LT2419104T (enExample)
MX (1) MX2011010782A (enExample)
NO (1) NO2419104T3 (enExample)
PL (1) PL2419104T3 (enExample)
PT (1) PT2419104T (enExample)
RU (1) RU2569056C2 (enExample)
SI (1) SI2419104T1 (enExample)
SM (1) SMT201800036T1 (enExample)
WO (1) WO2010120695A2 (enExample)
ZA (1) ZA201107490B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
JP6009080B2 (ja) 2012-08-16 2016-10-19 ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ 老化及び認知症の予防及び／または治療活性を有する乳酸菌
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
RS61704B1 (sr) 2017-05-24 2021-05-31 H Lundbeck As Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
JP7282028B2 (ja) 2017-06-02 2023-05-26 富士フイルム富山化学株式会社 脳萎縮予防または治療剤
CA3069989C (en) 2017-07-31 2025-05-06 Alfasigma S.P.A. METHODS FOR TREATING GASTROPARESIA SYMPTOMS USING VELUSETRAG

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108127A2 (en) * 2005-04-06 2006-10-12 Theravance, Inc. Crystalline form of a quinolinone-carboxamide compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124730T2 (de) * 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108127A2 (en) * 2005-04-06 2006-10-12 Theravance, Inc. Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
US20140057939A1 (en) 2014-02-27
JP2012523437A (ja) 2012-10-04
CY1119800T1 (el) 2018-06-27
HRP20180018T1 (hr) 2018-02-09
BRPI1013777A2 (pt) 2016-04-05
US8404711B2 (en) 2013-03-26
KR20120017421A (ko) 2012-02-28
LT2419104T (lt) 2018-02-12
IL215660A0 (en) 2012-01-31
WO2010120695A3 (en) 2010-12-02
EP2419104B1 (en) 2017-11-08
NO2419104T3 (enExample) 2018-04-07
PT2419104T (pt) 2018-01-31
DK2419104T3 (en) 2018-02-05
AU2010236734A1 (en) 2011-11-03
RU2569056C2 (ru) 2015-11-20
WO2010120695A2 (en) 2010-10-21
BRPI1013777A8 (pt) 2017-09-19
EP2419104A2 (en) 2012-02-22
PL2419104T3 (pl) 2018-04-30
SMT201800036T1 (it) 2018-03-08
ZA201107490B (en) 2012-06-27
US20100261752A1 (en) 2010-10-14
AU2010236734A8 (en) 2012-02-16
RU2011146032A (ru) 2013-05-20
ES2654930T3 (es) 2018-02-15
CN105832735A (zh) 2016-08-10
HUE038141T2 (hu) 2018-10-29
SI2419104T1 (en) 2018-03-30
CA2758321A1 (en) 2010-10-21
MX2011010782A (es) 2012-01-20
CN102395371A (zh) 2012-03-28

Similar Documents

Publication Publication Date Title
US8404711B2 (en) 5-HT4 receptor agonist compounds for treatment of cognitive disorders
JP6050115B2 (ja) アルツハイマー型認知症を治療するための方法及び組成物
AU2009229372C1 (en) Use and composition for treating dementia
KR102559354B1 (ko) 치매 치료
NZ337400A (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo
US6117890A (en) Method for treating bipolar disorder
HK1165722B (en) Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders
HK1165722A (en) Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders
WO1998005324A1 (en) Method for treating bipolar disorder
EP4217063A1 (en) Pharmaceutical combination for the treatment of human hypocholinergic disorders
AU2016231489B2 (en) Composition for treating dementia
AU2016231493B2 (en) Composition for treating dementia
AU2014277685B2 (en) Composition for treating dementia
HK1239557A1 (en) Combination of a nspacha (peripheral anticholinergic agent) like solifenacin and an achei (acetyl choline esterase inhibitor) like donepezil for treating dementia

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 25, NO 43, PAGE(S) 5428 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME THERAVANCE, INC., APPLICATION NO. 2010236734, UNDER INID (54) CORRECT THE TITLE TO 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS

PC1 Assignment before grant (sect. 113)

Owner name: THERAVANCE BIOPHARMA R&D IP, LLC

Free format text: FORMER APPLICANT(S): THERAVANCE, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired